Dr. Roychowdhury on FGFR Mutations in Intrahepatic Cholangiocarcinoma

Publication
Video
Supplements and Featured PublicationsNovel Therapeutic Approaches to Target FGFR Mutations in Solid Tumors
Volume 1
Issue 1

Sameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.

Sameek Roychowdhury, MD, PhD, medical oncologist, assistant professor, the Department of Internal Medicine and the Department of Pharmacology, The Ohio State University, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma (ICC).

FGFR mutations, which activate the FGFR receptor and cause abnormal signaling that affects cell growth, are most common in ICC, plus urothelial or bladder cancers, Roychowdhury says. Specifically, FGFR2 mutations tend to be more common in ICC, ranging from 10% to 15% of patients in that subset, Roychowdhury adds. However, FGFR3 mutations are more common in bladder cancer, appearing in 15% to 20% of that subset of patients, Roychowdhury explains.

Additionally, FGFR3 point mutations tend to occur more often in bladder cancer, whereas in ICC, FGFR2 gene fusions or rearrangements are typical, Roychowdhury continues. Despite these tendencies, a variety of FGFR mutations can present in these cancers, Roychowdhury concludes.

Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Haeseong Park, MD, MPH
Matthew P. Goetz, MD
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center